麗珠醫藥(01513.HK)擬為控股附屬麗健動保不超2.3億元融資提供擔保
格隆匯5月13日丨麗珠醫藥(01513.HK)公吿,為滿足麗珠醫藥集團股份有限公司(以下簡稱“公司”)控股附屬公司麗健(廣東)動物保健有限公司(以下簡稱“麗健動保”)經營業務的需要,公司於2024年5月13日召開了第十一屆董事會第十六次會議,審議通過了《關於公司為控股附屬公司麗健動保提供融資擔保的議案》(以下簡稱“本議案”,審議本議案時,關連董事朱保國、俞雄、邱慶豐及唐陽剛均已迴避表決,表決情況:同意7票,反對0票,棄權0票),同意公司為麗健動保向交通銀行股份有限公司等銀行申請最高不超過人民幣共計2.3億元整或等值外幣的授信融資提供連帶責任擔保。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.